First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers

Summary

The goal of this study is to identify a safe and tolerated dose of the orally administered DHX9 inhibitor ATX-559. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-559 in patients with advanced solid tumors and molecularly defined cancers.

Timeline

Start

2024-10-11

Primary completion

2026-01-09

Completion

2026-01-09

Outcome

Outcome not reported

Stopped: “The study was terminated by sponsor based on the adverse event profile.”

Drugs

Indications